Paramount Global (Formerly Viacomcbs INC.)
Entertainment and media company.
Based in DC
🤖
AI Overview
With $1.1M in lobbying spend across 28 quarterly filings, Paramount Global (Formerly Viacomcbs INC.) is a significant lobbying presence. They deploy 12 individual lobbyists Their lobbying covers 5 issue areas. Active from 2018 to 2025.
$1.1M
Total Spend
8
Years Active
1
Firms Hired
12
Lobbyists Deployed
5
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $80K |
| 2019 | $80K |
| 2020 | $10K |
| 2021 | $30K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $250K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Taxation, Trade, Media/Information, Defense, Communications
- •Legislative provisions related to the film industry.
- •Legislative issues related to patents.
Related Analysis
📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders
🏭 Defense Lobbying
Industry overview and top spenders
🏭 Tech Lobbying
Industry overview and top spenders
Related Investigations
The 22,000% ROI
When lobbying spending yields outsized returns.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Lobbying vs. Federal Contracts
How lobbying spending correlates with contract awards.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.